189 related articles for article (PubMed ID: 35857191)
1. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis.
Zhou Y; Xie W; Wang L; Zhu X; Li J; Liu L; Zhu S; Wang L
Drug Saf; 2022 Sep; 45(9):951-959. PubMed ID: 35857191
[TBL] [Abstract][Full Text] [Related]
2. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
[TBL] [Abstract][Full Text] [Related]
3. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
Mendes D; Alves C; Batel-Marques F
J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
[TBL] [Abstract][Full Text] [Related]
4. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660
[TBL] [Abstract][Full Text] [Related]
5. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B
Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333
[TBL] [Abstract][Full Text] [Related]
6. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database.
Saliba L; Moulis G; Abou Taam M; Rousseau V; Chebane L; Petitpain N; Baldin B; Pugnet G; Montastruc JL; Bagheri H
Fundam Clin Pharmacol; 2016 Apr; 30(2):162-71. PubMed ID: 26604187
[TBL] [Abstract][Full Text] [Related]
11. Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance Center.
Davidson L; Van den Reek JMPA; Van Hunsel F; De Jong EMGJ; Kullberg BJ
Acta Derm Venereol; 2022 Feb; 102():adv00648. PubMed ID: 35088874
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced vitiligo: a case/non-case study in Vigibase
Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
[TBL] [Abstract][Full Text] [Related]
13. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
[TBL] [Abstract][Full Text] [Related]
14. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase
Dernoncourt A; Liabeuf S; Bennis Y; Masmoudi K; Bodeau S; Laville S; Hurtel-Lemaire AS; Gras-Champel V; Batteux B
BioDrugs; 2023 Jan; 37(1):73-87. PubMed ID: 36401769
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
Dernoncourt A; Schmidt J; Duhaut P; Liabeuf S; Gras-Champel V; Masmoudi K; Bennis Y; Batteux B
Fundam Clin Pharmacol; 2022 Feb; 36(1):199-209. PubMed ID: 33973280
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
18. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016.
Ha D; Lee SE; Song I; Lim SJ; Shin JY
Clin Rheumatol; 2020 Feb; 39(2):347-355. PubMed ID: 31673980
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
20. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]